Table 1 Baseline characteristics stratified by cognitive decline.
From: Biomarker and cognitive decline in atrial fibrillation: a prospective cohort study
Cognitive decline | Overall | No | Yes | p value |
|---|---|---|---|---|
Number of patients | 1440 | 1347 | 93 | |
Female sex | 360 (25.0%) | 340 (25.2%) | 20 (21.5%) | 0.496 |
Age, years | 71.9 (8.31) | 71.5 (8.24) | 77.1 (7.59) | < 0.001 |
BMI, kg/m2 | 27.7 (4.59) | 27.7 (4.59) | 26.9 (4.51) | 0.054 |
Current smoking | 96 (6.7%) | 89 (6.6%) | 7 (7.5%) | 0.451 |
Education level | 0.246 | |||
Advanced | 596 (41.4%) | 551 (40.9%) | 45 (48.4%) | |
Basic | 150 (10.4%) | 139 (10.3%) | 11 (11.8%) | |
Middle | 693 (48.1%) | 656 (48.7%) | 37 (39.8%) | |
Missing | 1 (0.1%) | 1 (0.1%) | 0 (0%) | |
Atrial fibrillation type | 0.007 | |||
Paroxysmal | 674 (46.8%) | 628 (46.6%) | 46 (49.5%) | |
Persistent | 320 (22.2%) | 429 (31.8%) | 17 (18.3%) | |
Permanent | 446 (31.0%) | 290 (21.5%) | 30 (32.3%) | |
CHA2DS2-VASc score | 0.003 | |||
0–1 | 233 (16.2%) | 226 (16.8%) | 7 (7.5%) | |
2 | 285 (19.8%) | 273 (20.3%) | 12 (12.9%) | |
3 | 327 (22.7%) | 306 (22.7%) | 21 (22.6%) | |
4 | 279 (19.4%) | 260 (19.3%) | 19 (20.4%) | |
≥ 5 | 316 (21.9%) | 282 (20.9%) | 34 (36.6%) | |
Systolic blood pressure, mmHg | 134 (18.2) | 134 (18.1) | 134 (20.6) | 0.786 |
Diastolic blood pressure, mmHg | 78.4 (11.6) | 78.6 (11.5) | 76.2 (13.0) | 0.048 |
History of heart failure | 313 (21.7%) | 288 (21.4%) | 25 (26.9%) | 0.265 |
Arterial hypertension | 958 (66.5%) | 894 (66.4%) | 64 (68.8%) | 0.711 |
Diabetes | 209 (14.5%) | 192 (14.3%) | 17 (18.3%) | 0.361 |
History of stroke | 173 (12.0%) | 151 (11.2%) | 22 (23.7%) | < 0.001 |
History of myocardial infarction | 212 (14.7%) | 191 (14.2%) | 21 (22.6%) | 0.039 |
Vascular disease | 462 (32.1%) | 424 (31.5%) | 38 (40.9%) | 0.078 |
History of major bleeding | 82 (5.7%) | 73 (5.4%) | 9 (9.7%) | 0.138 |
Medications | ||||
Oral anticoagulation* | 1293 (89.8%) | 1206 (89.5%) | 87 (93.5%) | 0.289 |
Non-VKA oral anticoagulants | 747 (51.9%) | 700 (52.0%) | 47 (50.5%) | 0.873 |
VKA oral anticoagulants | 545 (37.8%) | 505 (37.5%) | 40 (43.0%) | 0.342 |
Antiplatelets | 282 (19.6%) | 266 (19.7%) | 16 (17.2%) | 0.641 |
